Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Carcinoma, Renal Cell 2Triple Negative Breast Neoplasms 1Sarcoma 1Neoplasms 1Metastatic Non-Squamous Non-Small Cell Lung Cancer 1Melanoma 1Lung Neoplasms 1Lung Diseases 1Liposarcoma 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Hepatocellular 1Carcinoma 1Breast Neoplasms 1Advanced Solid Tumors 1

Interventions

Pemetrexed 3Carboplatin 3selpercatinib 2pralsetinib 2pembrolizumab 2sotorasib 1sitravatinib 1patritumab 1osimertinib 1demcizumab 1cobimetinib 1atezolizumab 1aflibercept 1Tyrosine Kinase Inhibitors 1Paclitaxel 1Nivolumab 1Ipilimumab 1Gemcitabine 1Erlotinib Hydrochloride 1Dasatinib 1Cisplatin 1Bevacizumab 1Afatinib 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lung Diseases × sitravatinib × Clear all
NCT04925986 2025-04-17

Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC

Yale University

Phase 2 Terminated
9 enrolled 15 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡